Advertisement
Erratum| Volume 153, P274, August 2021

Download started.

Ok

Erratum to ‘Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis’ [Eur J Cancer 149 (2021) 134–152]

Published:June 25, 2021DOI:https://doi.org/10.1016/j.ejca.2021.06.001
Erratum to ‘Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis’ [Eur J Cancer 149 (2021) 134–152]
Previous ArticleResponse to letter entitled: ‘Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors’
      The publisher regrets that errors were made regarding the named trial PRIMA in section 4.4. ‘Results based on mutational status’.
      The sentence “Intriguingly, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) trial in ovarian cancer was able to identify a PFS improvement with niraparib monotherapy in HRR-proficient MOC [31].” should have appeared as follows
      “Intriguingly, the PRIMA trial in ovarian cancer was able to identify a PFS improvement with niraparib monotherapy in HRR-proficient MOC [31].”
      The publisher would like to apologise for any inconvenience caused.

      Article info

      Publication history

      Published online: June 25, 2021

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2021.06.001

      Copyright

      © 2021 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX